查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
罕见病基因检测市场规模、份额和趋势分析报告：按疾病类型（神经病学、CVD）、专业（分子、生化）、技术（NGS、基于PCR）、用户、细分市场预测，2022-2030
市场调查报告书
商品编码
1122146

罕见病基因检测市场规模、份额和趋势分析报告：按疾病类型（神经病学、CVD）、专业（分子、生化）、技术（NGS、基于PCR）、用户、细分市场预测，2022-2030

Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report By Disease Type (Neurological, CVDs), By Specialty (Molecular, Biochemical), By Technology (NGS, PCR-based), By End Use, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

罕见病基因检测市场增长和趋势

根据 Grand View Research, Inc. 的一份新报告，到 2030 年，全球罕见病基因检测市场规模预计将达到 25.2 亿美元，在预测期内的复合年增长率为 13.94%。对抗罕见疾病的有效监管计划是该行业的主要驱动力之一。此外，提供相关疾病数据和相关信息的大量註册机构的存在促进了过去几年的收入增长。预计将继续召开会议以提高对罕见和超罕见疾病的认识，以推动诊断试剂盒和服务的采用。例如，位于英国、德国、荷兰和波兰的 Ergomed 和 PSR Orphanexpert 正在参与旨在提高对该领域认识的各种活动。

此外，加拿大罕见病组织 (CORD) 提供了一个强大的平台，用于简化专门用于管理该疾病患者的医疗保健政策和医疗保健系统。该机构与临床医生、研究人员、政府和诊断行业合作，推动该国所有罕见疾病的研发、诊断、治疗和服务提供。根据美国国立卫生研究院 (NIH) 的数据，约有 3000 万美国人被证实患有 7,000 多种已知罕见疾病中的一种。随着意识的提高，预计未来接受疾病检测的患者人数将会增加。在美国，设立罕见病日是为了提高认识并促进该领域的发展。

罕见病临床研究网络 (RDCRN) 的存在也是一个行业积极的、由 NIH 资助的研究网络，由 23 个活跃的财团和研究小组组成，包括致力于诊断和治疗疾病的患者、研究人员和临床医生。在 COVID-19 大流行中，患有未确诊罕见病的患者面临着重大的健康挑战。根据一组美国研究人员于 2021 年 1 月发表的一项研究，迫切需要开发能够缓解影响患有罕见和未确诊疾病 (RUD) 的患者和家庭的严峻挑战的方法。这些挑战包括诊断和预后的不确定性以及医疗复杂性，这可能导致健康状况恶化。

为了应对大流行带来的挑战，患者倡导团体和专业团体积极参与这些挑战。例如，稀有染色体倡导组织 (Unique)、英国医学基因组学学会和英国遗传联盟正在积极努力支持、倡导和告知患有该疾病的患者。一些罕见病仍未分类。慈善机构 SWAN UK 估计，英国每年约有 6,000 名儿童出生时患有遗传疾病，但该机构表示，这些疾病非常罕见，无法命名。你不能。因此，目前不可能根据证据做出适当的诊断或预测治疗的预后。目前，据说在英国接受基因检测的儿童中约有 50% 没有得到明确的诊断。

大约 50% 的学习障碍儿童和 60% 的先天性疾病儿童没有得到明确的诊断以确定他们的残疾原因。此外，患者和家属对诊断和基因检测缺乏认识进一步阻碍了该行业的发展。北美在 2021 年主导了该行业，原因是其罕见病高发、大量註册、在该领域拥有相当规模的研发设施以及对诊断的大量投资。由于存在大量专注于疾病控制的组织，预计亚太地区将在预测期内实现最快的复合年增长率。

罕见病基因检测市场报告亮点

2021年，免疫疾病领域将占据很大份额。增加多发性硬化症病例将推动增长，因为它是该细分市场的重点关注领域之一。

从技术上看，NGS 细分市场预计将在 2022 年至 2030 年期间实现最快的复合年增长率。

这是由于基于 NGS 的基因组可用于测试癌症、神经系统疾病、心血管疾病、儿童疾病、精神疾病和其他罕见疾病的可用性和采用。

由于在研究和临床环境中的广泛采用，分子基因检测专业部门在 2021 年占最大的收入份额。增加免 CLIA 分子遗传学检测也提供了有利可图的增长机会

研究机构和 CRO 最终用户部门在 2021 年领先行业，因为研究机构和 CRO 进行了大量的基因测试

目录

第一章研究方法论

  • 调查假设
  • 调查方法
  • 信息采购
  • 信息或数据分析
  • 市场製定和验证
  • 市场模式
    • 市场研究，按疾病分类
    • 技术市场研究
    • 市场研究，按专业
    • 按最终用途进行的市场研究
    • 区域分析
    • 公司市场份额分析

第二章执行摘要

  • 市场概况

3. 市场变量、趋势和范围

  • 市场细分
  • 罕见病基因检测市场：行业金字塔分析
    • 母公司市场展望
    • 相关/子公司市场展望
  • 2021 年技术渗透率和增长前景图
  • 按因素（政法、经济、技术）的 SWOT 分析
  • 波特五力分析
  • COVID-19 影响分析
    • COVID-19 期间的罕见病基因检测解决方案

第四章行业展望

  • 市场动态
    • 市场驱动力分析
      • 扩大罕见病患者登记
      • 降低测序成本和疾病诊断的技术进步
      • 启动罕见病诊断项目和新产品开发
    • 市场约束分析
      • 缺乏有效的诊断框架
      • 与基因检测和数据管理相关的技术挑战
    • 市场机会分析
      • 政府和监管部门对罕见病诊断的支持
    • 市场问题分析
      • 对罕见病的认识有限
  • 监管框架
    • 美国
    • 欧洲
    • 中国
    • 日本
  • 重大交易及战略联盟分析
    • 新产品发布
    • 併购
    • 合伙
  • 罕见病基因检测市场：公司市场份额分析

第 5 章按疾病分类的业务分析

  • 罕见病基因检测市场：疾病类型变异分析
  • 神经系统疾病
  • 免疫疾病
  • 血液病
  • 内分泌/代谢疾病
  • 癌症
  • 肌肉骨骼疾病
  • 心血管疾病 (Cvd)
  • 皮肤病
  • 其他罕见病

第六章技术业务分析

  • 罕见病基因检测市场：技术波动分析
  • 新一代测序 (NGS)
    • 全外显子组测序 (WES)
    • 全基因组测序（WGS）
  • 阵列技术
  • 基于 PCR 的检测
  • 鱼
  • 桑格测序
  • 核型分析

第 7 章专业业务分析

  • 分子遗传学检测
  • 染色体基因检测
  • 生化基因检测

第 8 章最终用途业务分析

  • 研究和CRO
  • 诊断实验室
  • 医院和诊所

第九章区域业务分析

  • 罕见病基因检测市场：区域趋势分析
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 西班牙
    • 法国
    • 意大利
    • 荷兰
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 新加坡
    • 澳大利亚
    • 东南亚
  • 拉丁美洲
    • 巴西
  • 中东和非洲
    • 南非

第十章公司简介

  • 战略框架
  • 公司参与者的分类
  • 公司简介
    • CENTOGENE NV
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • INVITAE CORPORATION
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • 3 BILLION, INC.
      • 公司简介
      • 产品基准
      • 战略举措
    • ARUP LABORATORIES
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • EUROFINS SCIENTIFIC
      • 公司简介
      • EUROFINS Genoma Group Srl a socio unico
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • STRAND LIFE SCIENCES
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • QUEST DIAGNOSTICS INCORPORATED
      • 公司简介
      • Blueprint Genetics Oy
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • PERKINELMER GENOMICS
      • 公司简介
      • 财务绩效
      • 产品基准
    • REALM IDX, INC.
      • 公司简介
      • Ambry Genetics
      • 公司简介
      • 财务绩效
      • 财务业绩：AMBRY GENETICS
      • 产品基准
      • 战略举措
    • PSOMAGEN INC. (MACROGEN, INC.)
      • 公司简介
      • 产品基准
      • 战略举措
    • BAYLOR GENETICS
      • 公司简介
      • 产品基准
      • 战略举措
    • COLOR GENOMICS, INC.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • HEALTH NETWORK LABORATORIES
      • 公司简介
      • 结缔组织基因检测
      • 公司简介
      • 产品基准
      • 战略举措
    • PREVENTION GENETICS
      • 公司简介
      • 产品基准
      • 战略举措
    • PROGENITY, INC.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • COOPERSURGICAL, INC.
      • 公司简介
      • Genesis Genetics
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • FULGENT GENETICS INC,
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • MYRIAD GENETICS, INC.
      • 公司简介
      • Counsyl, Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 公司简介
      • Sequenom
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • OPKO HEALTH, INC.
      • 公司简介
      • Bio-Reference Laboratories
      • 公司简介
      • GENEDX
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • ARTEMIS DNA
      • 公司简介
      • 产品基准
Product Code: GVR-4-68038-695-0

Rare Disease Genetic Testing Market Growth & Trends:

The global rare disease genetic testing market size is expected to reach USD 2.52 billion by 2030, registering a CAGR of 13.94% over the forecast period, according to a new report by Grand View Research, Inc. Effective regulatory plans to combat rare disease is one of the key drivers of the industry. Furthermore, the presence of a substantial number of registries that provide data and relevant information about related diseases has aided in revenue growth over the past years. Ongoing conferences to raise awareness about rare and ultra-rare conditions are anticipated to boost the adoption of diagnostic kits and services. For instance, Ergomed and PSR Orphan Experts, with their offices in the U.K., Germany, the Netherlands, Poland, and other countries, participate in various activities that are aimed at raising awareness in this area.

Moreover, the Canadian Organization for Rare Disorders (CORD) offers a strong platform to streamline health policy and a healthcare system that is dedicated to the management of patients with disorders. The agency works with clinicians, researchers, governments, and the diagnostic industry to advance R&D, diagnosis, treatment, and service availability for all rare conditions in the country. As per the National Institutes of Health (NIH), around 30 million Americans have been identified with one of 7,000+ known rare diseases. The number of patients undergoing disease testing is expected to increase in the coming years with growing awareness. The U.S. celebrates Rare Disease Day and promotes developments in this area by raising awareness.

In addition, the presence of the Rare Diseases Clinical Research Network (RDCRN), an NIH-funded research network of 23 active consortia or research groups that includes patients, researchers, and clinicians who are focused on the diagnosis & treatment of disorders is anticipated to positively impact the industry. Amidst the COVID-19 pandemic, patients with undiagnosed and rare diseases have been facing significant health challenges. According to a study published in January 2021 by a group of researchers from the U.S., there is an urgent need for the development of approaches that can reduce the serious challenges affecting Rare & Undiagnosed diseases (RUD) patients and families. The challenges include diagnostic and/or prognostic uncertainty coupled with medical complexity leading to poor health outcomes.

In response to the challenges created by the pandemic, patient support groups and professional societies are actively involved in addressing these challenges. For instance, the Rare Chromosome Support Group (Unique), the British Society for Genomic Medicine, and Genetic Alliance U.K. are actively involved in supporting, advocating, and providing information to patients with diseases. Several rare conditions remain unclassified. The charity SWAN U.K. estimated that around 6,000 children are born each year with genetic conditions in the U.K. As per the agency, the conditions are extremely rare and cannot be named. Thus, there is a lack of proper diagnosis and prognosis for evidence-based treatment. At present, around 50% of the children who undergo genetic testing in the U.K. would not receive a confirmed diagnosis.

Around 50% of the children with learning disabilities and approximately 60% of children with congenital conditions do not receive a definitive diagnosis to identify the cause of their disabilities. Furthermore, the lack of awareness among patients and families about diagnosis and genetic testing has further impeded the industry's growth. North America dominated the industry in 2021 due to the high incidence of rare diseases, a large number of registries, the presence of substantial numbers of R&D facilities in this area, and extensive investments in diagnosis. Asia Pacific is expected to register the fastest CAGR during the forecast years owing to the presence of a substantial number of organizations that are focusing on disease management.

Rare Disease Genetic Testing Market Report Highlights:

  • The immunological disorders segment held a significant revue share in 2021. A rise in the cases of multiple sclerosis drives the growth as is one of the key focus areas in this segment
  • Based on technology, the NGS segment is expected to register the fastest CAGR from 2022 to 2030
  • This is due to the availability & adoption of NGS-based gene panels for cancer, neurologic disease, CVD, pediatric conditions, psychiatric disorders, and another rare disease testing
  • The molecular genetic tests specialty segment held the largest revenue share in 2021 due to the high adoption in research & clinical settings. A rise in CLIA-waived molecular genetic tests also offers lucrative growth opportunities
  • The research laboratories & CROs end-user segment led the industry in 2021 owing to a large number of genetic tests conducted in research laboratories and CROs

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Research Assumptions
  • 1.2 Research Methodology
  • 1.3 Information Procurement
  • 1.4 Information or Data Analysis
  • 1.5 Market Formulation & Validation
  • 1.6 Market Model
    • 1.6.1 Market Study, By Disease
    • 1.6.2 Market Study, By Technology
    • 1.6.3 Market Study, By Specialty
    • 1.6.4 Market Study, By End Use
    • 1.6.5 Regional Analysis
    • 1.6.6 Company Market Share Analysis

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Market Segmentation
  • 3.2 Rare Disease Genetic Testing Market: Industry Pyramid Analysis
    • 3.2.1 Parent Market Outlook
    • 3.2.2 Related/Ancillary Market Outlook
  • 3.3 Penetration and Growth Prospect Mapping for Technology, 2021
  • 3.4 SWOT analysis, by a factor (Political & legal, economic, and technological)
  • 3.5 Porter's Five Forces Analysis
  • 3.6 COVID-19 Impact Analysis
    • 3.6.1 Rare Disease Genetic Testing Solutions During Covid-19

Chapter 4 Industry Outlook

  • 4.1 Market Dynamics
    • 4.1.1 Market Driver Analysis
      • 4.1.1.1 Expanding patient registry for rare disease
      • 4.1.1.2 Declining Sequencing Cost & Technological Advancements In Disease Diagnosis
      • 4.1.1.3 Launch Of Programs & New Product Development In Rare Disease diagnosis
    • 4.1.2 Market Restraint Analysis
      • 4.1.2.1 Absence Of Effective Diagnosis Framework
      • 4.1.2.2 Technical Challenges Associated With Genetic Tests & Data Management
    • 4.1.3 Market Opportunity Analysis
      • 4.1.3.1 Government & Regulatory Support For Rare Disease Diagnosis
    • 4.1.4 Market Challenge Analysis
      • 4.1.4.1 Limited Awareness about The Rare Disease Conditions
  • 4.2 Regulatory Framework
    • 4.2.1 U.S.
    • 4.2.2 Europe
    • 4.2.3 China
    • 4.2.4 Japan
  • 4.3 Major Deals And Strategic Alliances Analysis
    • 4.3.1 New Product Launch
    • 4.3.2 Mergers And Acquisitions
    • 4.3.3 Partnerships
  • 4.4 Rare Disease Genetic Testing Market: Company Market Share Analysis

Chapter 5 Disease Type Business Analysis

  • 5.1 Rare Disease Genetic Testing Market: Disease Type Movement Analysis
  • 5.2 Neurological Diseases
    • 5.2.1 Global Genetic Testing Market For Rare Neurological Diseases, 2018 - 2030 (USD Million)
  • 5.3 Immunological Disorders
    • 5.3.1 Global Genetic Testing Market For Rare Immunological Disorders, 2018 - 2030 (USD Million)
  • 5.4 Hematology Diseases
    • 5.4.1 Global Genetic Testing Market For Rare Hematology Diseases, 2018 - 2030 (USD Million)
  • 5.5 Endocrine & Metabolism Diseases
    • 5.5.1 Global Genetic Testing Market For Rare Endocrine & Metabolism Diseases, 2018 - 2030 (USD Million)
  • 5.6 Cancer
    • 5.6.1 Global Genetic Testing Market For Rare Cancer Forms, 2018 - 2030 (USD Million)
  • 5.7 Musculoskeletal Disorders
    • 5.7.1 Global Genetic Testing Market For Rare Musculoskeletal Disorders, 2018 - 2030 (USD Million)
  • 5.8 Cardiovascular Disorders (Cvd)
    • 5.8.1 Global Genetic Testing Market For Rare Cardiovascular Disorders, 2018 - 2030 (USD Million)
  • 5.9 Dermatology Diseases
    • 5.9.1 Global Genetic Testing Market For Rare Dermatology Diseases, 2018 - 2030 (USD Million)
  • 5.10 Other Rare Diseases
    • 5.10.1 Global Genetic Testing Market For Other Rare Diseases, 2018 - 2030 (USD Million)

Chapter 6 Technology Business Analysis

  • 6.1 Rare Disease Genetic Testing Market: Technology Movement Analysis
  • 6.2 Next Generation Sequencing (NGS)
    • 6.2.1 Global NGS-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
    • 6.2.2 Whole Exome Sequencing (WES)
      • 6.2.2.1 Global WES-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
    • 6.2.3 Whole Genome Sequencing (WGS)
      • 6.2.3.1 Global WGS-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.3 Array Technology
    • 6.3.1 Global Array Technology-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.4 Pcr-Based Testing
    • 6.4.1 Global Pcr-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.5 Fish
    • 6.5.1 Global Fish-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.6 Sanger Sequencing
    • 6.6.1 Global Sanger Sequencing-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.7 Karyotyping
    • 6.7.1 Global Karyotyping-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)

Chapter 7 Speciality Business Analysis

  • 7.1 Molecular Genetic Tests
    • 7.1.1 Global Molecular Genetic Tests Market For Rare Diseases, 2018 - 2030 (USD Million)
  • 7.2 Chromosomal Genetic Tests
    • 7.2.1 Global Chromosomal Genetic Tests Market For Rare Diseases, 2018 - 2030 (USD Million)
  • 7.3 Biochemical Genetic Tests
    • 7.3.1 Global Biochemical Genetic Tests Market For Rare Diseases, 2018 - 2030 (USD Million)

Chapter 8 End-Use Business Analysis

  • 8.1 Research Laboratories & CROs
    • 8.1.1 Global Research Laboratories & CROs-based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 8.2 Diagnostic Laboratories
    • 8.2.1 Global Diagnostic Laboratories-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 8.3 Hospitals & Clinics
    • 8.3.1 Global Hospitals & Clinics-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)

Chapter 9 Regional Business Analysis

  • 9.1 Rare Diseases Genetic Testing Market: Regional Movement Analysis
  • 9.2 North America
    • 9.2.1 North America Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 U.S. Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.2.3 Canada
      • 9.2.3.1 Canada Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.3 Europe
    • 9.3.1 Europe Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.2 Germany
      • 9.3.2.1 Germany Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.3 U.K.
      • 9.3.3.1 U.K. Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.4 Spain
      • 9.3.4.1 Spain Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.5 France
      • 9.3.5.1 France Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.6 Italy
      • 9.3.6.1 Italy Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.7 The Netherlands
      • 9.3.7.1 The Netherlands Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Japan Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.3 China
      • 9.4.3.1 China Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.4 India
      • 9.4.4.1 India Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.5 South Korea
      • 9.4.5.1 South Korea Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.6 Singapore
      • 9.4.6.1 Singapore Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.7 Australia
      • 9.4.7.1 Australia Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.8 South East Asia
      • 9.4.8.1 South East Asia Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Latin America Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Brazil Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.6 Middle East And Africa
    • 9.6.1 Middle-East And Africa Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 South Africa rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Strategy Framework
  • 10.2 Company Participant categorization
  • 10.3 Company Profiles
    • 10.3.1 CENTOGENE N.V.
      • 10.3.1.1 Company overview
      • 10.3.1.2 Financial performance
      • 10.3.1.3 Product benchmarking
      • 10.3.1.4 Strategic initiatives
    • 10.3.2 INVITAE CORPORATION
      • 10.3.2.1 Company overview
      • 10.3.2.2 Financial Performance
      • 10.3.2.3 Product benchmarking
      • 10.3.2.4 Strategic initiatives
    • 10.3.3 3 BILLION, INC.
      • 10.3.3.1 Company overview
      • 10.3.3.2 Product benchmarking
      • 10.3.3.3 Strategic initiatives
    • 10.3.4 ARUP LABORATORIES
      • 10.3.4.1 Company overview
      • 10.3.4.2 Financial Performance
      • 10.3.4.3 Product benchmarking
      • 10.3.4.4 Strategic initiatives
    • 10.3.5 EUROFINS SCIENTIFIC
      • 10.3.5.1 Company overview
      • 10.3.5.2 EUROFINS Genoma Group Srl a socio unico
      • 10.3.5.2.1 Company Overview
      • 10.3.5.3 Financial Performance
      • 10.3.5.4 Product benchmarking
      • 10.3.5.5 Strategic initiatives
    • 10.3.6 STRAND LIFE SCIENCES
      • 10.3.6.1 Company overview
      • 10.3.6.2 Financial Performance
      • 10.3.6.3 Product benchmarking
      • 10.3.6.4 Strategic initiatives
    • 10.3.7 QUEST DIAGNOSTICS INCORPORATED
      • 10.3.7.1 Company overview
      • 10.3.7.2 Blueprint Genetics Oy
      • 10.3.7.2.1 Company Overview
      • 10.3.7.3 Financial Performance
      • 10.3.7.4 Product benchmarking
      • 10.3.7.5 Strategic initiatives
    • 10.3.8 PERKINELMER GENOMICS
      • 10.3.8.1 Company overview
      • 10.3.8.2 Financial Performance
      • 10.3.8.3 Product benchmarking
    • 10.3.9 REALM IDX, INC.
      • 10.3.9.1 Company overview
      • 10.3.9.2 Ambry Genetics
      • 10.3.9.2.1 Company Overview
      • 10.3.9.3 Financial Performance
      • 10.3.9.3.1 Financial Performance: AMBRY GENETICS
      • 10.3.9.4 Product benchmarking
      • 10.3.9.5 Strategic initiatives
    • 10.3.10 PSOMAGEN INC. (MACROGEN, INC.)
      • 10.3.10.1 Company overview
      • 10.3.10.2 Product benchmarking
      • 10.3.10.3 Strategic initiatives
    • 10.3.11 BAYLOR GENETICS
      • 10.3.11.1 Company overview
      • 10.3.11.2 Product benchmarking
      • 10.3.11.3 Strategic initiatives
    • 10.3.12 COLOR GENOMICS, INC.
      • 10.3.12.1 Company overview
      • 10.3.12.2 Financial performance
      • 10.3.12.3 Product benchmarking
      • 10.3.12.4 Strategic initiatives
    • 10.3.13 HEALTH NETWORK LABORATORIES
      • 10.3.13.1 Company overview
      • 10.3.13.2 Connective Tissue Gene Tests
      • 10.3.13.2.1 Company overview
      • 10.3.13.3 Product benchmarking
      • 10.3.13.4 Strategic initiatives
    • 10.3.14 PREVENTION GENETICS
      • 10.3.14.1 Company overview
      • 10.3.14.2 Product benchmarking
      • 10.3.14.3 Strategic initiatives
    • 10.3.15 PROGENITY, INC.
      • 10.3.15.1 Company overview
      • 10.3.15.2 Financial performance
      • 10.3.15.3 Product benchmarking
      • 10.3.15.4 Strategic initiatives
    • 10.3.16 COOPERSURGICAL, INC.
      • 10.3.16.1 Company overview
      • 10.3.16.2 Genesis Genetics
      • 10.3.16.2.1 Company overview
      • 10.3.16.3 Financial performance
      • 10.3.16.4 Product benchmarking
      • 10.3.16.5 Strategic initiatives
    • 10.3.17 FULGENT GENETICS INC,
      • 10.3.17.1 Company overview
      • 10.3.17.2 Financial Performance
      • 10.3.17.3 Product benchmarking
      • 10.3.17.4 Strategic initiatives
    • 10.3.18 MYRIAD GENETICS, INC.
      • 10.3.18.1 Company overview
      • 10.3.18.2 Counsyl, Inc.
      • 10.3.18.2.1 Company overview
      • 10.3.18.3 Financial Performance
      • 10.3.18.4 Product benchmarking
      • 10.3.18.5 Strategic initiatives
    • 10.3.19 LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 10.3.19.1 Company overview
      • 10.3.19.2 Sequenom
      • 10.3.19.2.1 Company overview
      • 10.3.19.3 Financial Performance
      • 10.3.19.4 Product benchmarking
      • 10.3.19.5 Strategic initiatives
    • 10.3.20 OPKO HEALTH, INC.
      • 10.3.20.1 Company overview
      • 10.3.20.2 Bio-Reference Laboratories
      • 10.3.20.2.1 Company overview
      • 10.3.20.2.2 GENEDX
      • 10.3.20.2.2.1 Company overview
      • 10.3.20.3 Financial Performance
      • 10.3.20.4 Product benchmarking
      • 10.3.20.5 Strategic initiatives
    • 10.3.21 ARTEMIS DNA
      • 10.3.21.1 Company overview
      • 10.3.21.2 Product benchmarking

List of Tables

  • Table 1 Inheritance pattern of rare diseases
  • Table 2 Distribution of registries by EU countries
  • Table 3 Rare disease policy and regulatory frameworks in EU
  • Table 4 North America rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 5 North America rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 6 North America NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 7 North America rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 8 North America rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 9 U.S. rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 10 U.S. rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 11 U.S. NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 12 U.S. rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 13 U.S. rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Canada rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 15 Canada rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 16 Canada NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 17 Canada rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 18 Canada rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 19 Europe rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 20 Europe rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 21 Europe NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 22 Europe rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 23 Europe rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Germany rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 25 Germany rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 26 Germany NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 27 Germany rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 28 Germany rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 29 U.K. rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 30 U.K. rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 31 U.K. NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 32 U.K. rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 33 U.K. rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Spain rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 35 Spain rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 36 Spain NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 37 Spain rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 38 Spain rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 39 France rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 40 France rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 41 France NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 42 France rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 43 France rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 44 Italy rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 45 Italy rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 46 Italy NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 47 Italy rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 48 Italy rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 49 Netherlands rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 50 Netherlands rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 51 Netherlands NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 52 Netherlands rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 53 Netherlands rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Japan rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 60 Japan rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 61 Japan NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 62 Japan rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 63 Japan rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 64 China rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 65 China rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 66 China NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 67 China rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 68 China rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 69 India rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 70 India rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 71 India NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 72 India rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 73 India rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 74 South Korea rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 75 South Korea rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 76 South Korea NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 77 South Korea rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 78 South Korea rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 79 Singapore rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 80 Singapore rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 81 Singapore NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 82 Singapore rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 83 Singapore rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 84 Australia rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 85 Australia rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 86 Australia NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 87 Australia rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 88 Australia rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 89 South East Asia rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 90 South East Asia rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 91 South East Asia NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 92 South East Asia rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 93 South East Asia rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 94 Latin America rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 95 Latin America rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 96 Latin America NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 97 Latin America rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 98 Latin America rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 99 Brazil rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 100 Brazil rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 101 Brazil NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 102 Brazil rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 103 Brazil rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 104 MEA rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 105 MEA rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 106 MEA NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 107 MEA rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 108 MEA rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 109 South Africa rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 110 South Africa rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 111 South Africa NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 112 South Africa rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 113 South Africa rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million) 

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain Based Sizing and Forecasting
  • Fig. 6 QFD Modelling for Market Share Assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Rare diseases by inheritance pattern
  • Fig. 9 Definition of rare diseases by region
  • Fig. 10 Prevalence of Multiple sclerosis
  • Fig. 11 Prevalence rate of selected rare diseases in 2021
  • Fig. 12 Distribution of research projects for rare diseases
  • Fig. 13 Penetration of technologies in the rare disease diagnostics market
  • Fig. 14 QFD modeling for market share assessment for specialty scope, by type
  • Fig. 15 Penetration by end-use settings
  • Fig. 16 Regional analysis of rare disease genetic testing market
  • Fig. 17 QFD modeling for company market share assessment
  • Fig. 18 QFD modeling workflow for company market share assessment
  • Fig. 19 Rare disease genetic testing market snapshot, 2021 (USD Million)
  • Fig. 21 Ancillary market analysis
  • Fig. 22 Penetration and growth prospect mapping for specialty, 2021
  • Fig. 23 SWOT analysis, by a factor (Political & legal, economic, and technological)
  • Fig. 24 Porter's Five Forces Analysis
  • Fig. 25 Rare disease genetic testing market driver impact
  • Fig. 26 Distribution of registries by affiliation in EU
  • Fig. 27 Illumina's sequencing cost per MB
  • Fig. 28 Rare disease genetic testing market restraint impact
  • Fig. 29 Challenges in rare disease diagnosis
  • Fig. 30 Company market share analysis
  • Fig. 31 Rare disease genetic testing market: Disease type outlook and key takeaways
  • Fig. 32 Rare disease genetic testing market: Disease type movement analysis
  • Fig. 33 Global genetic testing market for rare neurology diseases, 2018 - 2030 (USD Million)
  • Fig. 34 Global genetic testing market for rare immunologic disorders, 2018 - 2030 (USD Million)
  • Fig. 35 Global genetic testing market for rare hematology diseases, 2018 - 2030 (USD Million)
  • Fig. 36 Global genetic testing market for rare endocrine & metabolism diseases, 2018 - 2030 (USD Million)
  • Fig. 37 Global genetic testing market for rare cancer forms, 2018 - 2030 (USD Million)
  • Fig. 38 Global genetic testing market for rare musculoskeletal disorders, 2018 - 2030 (USD Million)
  • Fig. 39 Global genetic testing market for rare cardiovascular disorders, 2018 - 2030 (USD Million)
  • Fig. 40 Global genetic testing market for rare dermatology diseases, 2018 - 2030 (USD Million)
  • Fig. 41 Global genetic testing market for other rare diseases, 2018 - 2030 (USD Million)
  • Fig. 42 Rare disease genetic testing market: Technology outlook and key takeaways
  • Fig. 43 Rare disease genetic testing market: Technology movement analysis
  • Fig. 44 DNA sequencing cost per genome
  • Fig. 45 DNA sequencing cost per genome
  • Fig. 46 Global NGS-based Rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 47 Comparison of growth in genetic testing units for exome & targeted exome, custom genes, large (>500 gene) panels
  • Fig. 48 Global WES-based rare disease genetic testing market 2018 - 2030 (USD Million)
  • Fig. 49 Global WGS-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 50 Global array specialty-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 51 Global PCR-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 52 Global FISH-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 53 Global sanger sequencing-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 54 Global karyotyping-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 55 Rare disease genetic testing market: Specialty outlook and key takeaways
  • Fig. 56 Rare disease genetic testing market: Specialty movement analysis
  • Fig. 57 DNA sequencing cost per Mb
  • Fig. 58 Global molecular genetic tests market for rare diseases, 2018 - 2030 (USD Million)
  • Fig. 59 Global chromosomal genetic tests market for rare diseases, 2018 - 2030 (USD Million)
  • Fig. 60 Global biochemical genetic tests market for rare diseases, 2018 - 2030 (USD Million)
  • Fig. 61 Rare disease genetic testing market: End-use outlook and key takeaways
  • Fig. 62 Rare disease genetic testing market: End-use movement analysis
  • Fig. 63 Global research laboratories & CROs-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 64 Global diagnostic laboratories-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 65 Global hospitals & clinics-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 66 Rare disease genetic testing market: Regional outlook and key takeaways
  • Fig. 67 Rare disease genetic testing market: Regional movement analysis
  • Fig. 68 North America
  • Fig. 69 North America rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 U.S.
  • Fig. 71 U.S. rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Canada
  • Fig. 73 Canada rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Europe
  • Fig. 75 Europe rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Germany
  • Fig. 77 Germany rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 U.K.
  • Fig. 79 U.K. rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Spain
  • Fig. 81 Spain rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 France
  • Fig. 83 France rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Italy
  • Fig. 85 Italy rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 The Netherlands
  • Fig. 87 The Netherlands rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Asia-Pacific
  • Fig. 89 Asia-Pacific rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Japan
  • Fig. 91 Japan rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 China
  • Fig. 93 China rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 India
  • Fig. 95 India rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 96 South Korea
  • Fig. 97 South Korea rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 Singapore
  • Fig. 99 Singapore rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 100 Australia
  • Fig. 101 Australia rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 102 South East Asia
  • Fig. 103 South East Asia rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 104 Latin America
  • Fig. 105 Latin America rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 106 Brazil
  • Fig. 107 Brazil rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 108 Middle East & Africa
  • Fig. 109 MEA rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 110 South Africa
  • Fig. 111 South Africa rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 112 Strategy framework
  • Fig. 113 Company participant categorization